Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72714
Title:
Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.
Authors:
Sarrazin, S; Adam, E; Lyon, Malcolm; Depontieu, F; Motte, V; Landolfi, C; Lortat-Jacob, H; Bechard, D; Lassalle, P; Delehedde, Maryse
Abstract:
Endocan, previously called endothelial cell specific molecule-1, is a soluble proteoglycan of 50 kDa, constituted of a mature polypeptide of 165 amino acids and a single dermatan sulphate chain covalently linked to the serine residue at position 137. This dermatan sulphate proteoglycan, which is expressed by the vascular endothelium, has been found freely circulating in the bloodstream of healthy subjects. Experimental evidence is accumulating that implicates endocan as a key player in the regulation of major processes such as cell adhesion, in inflammatory disorders and tumor progression. Inflammatory cytokines such as TNF-alpha, and pro-angiogenic growth factors such as VEGF, FGF-2 and HGF/SF, strongly increased the expression, synthesis or the secretion of endocan by human endothelial cells. Endocan is clearly overexpressed in human tumors, with elevated serum levels being observed in late-stage lung cancer patients, as measured by enzyme-linked immunoassay, and with its overexpression in experimental tumors being evident by immunohistochemistry. Recently, the mRNA levels of endocan have also been recognized as being one of the most significant molecular signatures of a bad prognosis in several types of cancer including lung cancer. Overexpression of this dermatan sulphate proteoglycan has also been shown to be directly involved in tumor progression as observed in mouse models of human tumor xenografts. Collectively, these results suggest that endocan could be a biomarker for both inflammatory disorders and tumor progression as well as a validated therapeutic target in cancer. On the basis of the recent successes of immunotherapeutic approaches in cancer, the preclinical data on endocan suggests that an antibody raised against the protein core of endocan could be a promising cancer therapy.
Affiliation:
ENDOTIS PHARMA, Parc Eurasanté, 70 rue du Dr. Yersin, 59120 Loos, France.
Citation:
Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. 2006, 1765 (1):25-37 Biochim. Biophys. Acta
Journal:
Biochimica et Biophysica Acta
Issue Date:
Jan-2006
URI:
http://hdl.handle.net/10541/72714
DOI:
10.1016/j.bbcan.2005.08.004
PubMed ID:
16168566
Type:
Article
Language:
en
ISSN:
0006-3002
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorSarrazin, S-
dc.contributor.authorAdam, E-
dc.contributor.authorLyon, Malcolm-
dc.contributor.authorDepontieu, F-
dc.contributor.authorMotte, V-
dc.contributor.authorLandolfi, C-
dc.contributor.authorLortat-Jacob, H-
dc.contributor.authorBechard, D-
dc.contributor.authorLassalle, P-
dc.contributor.authorDelehedde, Maryse-
dc.date.accessioned2009-07-07T10:29:23Z-
dc.date.available2009-07-07T10:29:23Z-
dc.date.issued2006-01-
dc.identifier.citationEndocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. 2006, 1765 (1):25-37 Biochim. Biophys. Actaen
dc.identifier.issn0006-3002-
dc.identifier.pmid16168566-
dc.identifier.doi10.1016/j.bbcan.2005.08.004-
dc.identifier.urihttp://hdl.handle.net/10541/72714-
dc.description.abstractEndocan, previously called endothelial cell specific molecule-1, is a soluble proteoglycan of 50 kDa, constituted of a mature polypeptide of 165 amino acids and a single dermatan sulphate chain covalently linked to the serine residue at position 137. This dermatan sulphate proteoglycan, which is expressed by the vascular endothelium, has been found freely circulating in the bloodstream of healthy subjects. Experimental evidence is accumulating that implicates endocan as a key player in the regulation of major processes such as cell adhesion, in inflammatory disorders and tumor progression. Inflammatory cytokines such as TNF-alpha, and pro-angiogenic growth factors such as VEGF, FGF-2 and HGF/SF, strongly increased the expression, synthesis or the secretion of endocan by human endothelial cells. Endocan is clearly overexpressed in human tumors, with elevated serum levels being observed in late-stage lung cancer patients, as measured by enzyme-linked immunoassay, and with its overexpression in experimental tumors being evident by immunohistochemistry. Recently, the mRNA levels of endocan have also been recognized as being one of the most significant molecular signatures of a bad prognosis in several types of cancer including lung cancer. Overexpression of this dermatan sulphate proteoglycan has also been shown to be directly involved in tumor progression as observed in mouse models of human tumor xenografts. Collectively, these results suggest that endocan could be a biomarker for both inflammatory disorders and tumor progression as well as a validated therapeutic target in cancer. On the basis of the recent successes of immunotherapeutic approaches in cancer, the preclinical data on endocan suggests that an antibody raised against the protein core of endocan could be a promising cancer therapy.en
dc.language.isoenen
dc.subjectCell Line Tumouren
dc.subjectCell Transformationen
dc.subjectLung Canceren
dc.subjectCancer Proteinsen
dc.subjectTumour Markersen
dc.subject.meshAmino Acid Sequence-
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCell Line, Tumor-
dc.subject.meshCell Transformation, Neoplastic-
dc.subject.meshDrug Delivery Systems-
dc.subject.meshEndothelial Cells-
dc.subject.meshGene Expression Regulation-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMolecular Sequence Data-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshProtein Conformation-
dc.subject.meshProteoglycans-
dc.subject.meshTranscription, Genetic-
dc.subject.meshTumor Markers, Biological-
dc.titleEndocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.en
dc.typeArticleen
dc.contributor.departmentENDOTIS PHARMA, Parc Eurasanté, 70 rue du Dr. Yersin, 59120 Loos, France.en
dc.identifier.journalBiochimica et Biophysica Actaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.